Outcomes of 2,111 COVID-19 hospitalised patients treated with 2 hydroxychloroquine/azithromycin and other regimens in Marseille, France: a 3 monocentric retrospective analysis
Lagier et al.,
Outcomes of 2,111 COVID-19 hospitalised patients treated with 2 hydroxychloroquine/azithromycin and other..,
Therapeutics and Clinical Risk Management, doi:10.2147/TCRM.S364022
Retrospective 2,011 hospitalized patients in France, median age 67, showing lower mortality with HCQ+AZ, and further benefit with the addition of zinc.
risk of death, 32.0% lower, HR 0.68, p = 0.004, treatment 93 of 1,270 (7.3%), control 146 of 841 (17.4%), NNT 10.0, adjusted per study, multivariable, Cox proportional hazards.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Lagier et al., 4 Jun 2021, retrospective, France, peer-reviewed, 32 authors.
Abstract: Therapeutics and Clinical Risk Management
Dovepress
open access to scientific and medical research
Therapeutics and Clinical Risk Management
For personal use only.
Open Access Full Text Article
ORIGINAL RESEARCH
Outcomes of 2111 COVID-19 Hospitalized Patients
Treated with Hydroxychloroquine/Azithromycin
and Other Regimens in Marseille, France, 2020:
A Monocentric Retrospective Analysis
Jean-Christophe Lagier 1,2 , Matthieu Million 1,2 , Sébastien Cortaredona 1,3 , Léa Delorme 1 ,
Philippe Colson 1,2 , Pierre-Edouard Fournier 1,3 , Philippe Brouqui 1,2 , Didier Raoult 1,2 ,
Philippe Parola 1,3
On behalf of the IHU Task Force
1
IHU-Méditerranée Infection, Marseille, France; 2MEPHI, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique
Hôpitaux de Marseille, Marseille, France; 3VITROME, Aix Marseille Université, Institut de Recherche pour le Développement, Assistance Publique
Hôpitaux de Marseille, Service de Santé des Armées, Marseille, France
Correspondence: Philippe Parola, Institut Hospitalo-Universitaire Méditerranée Infection, 19-21 Boulevard Jean Moulin, Marseille, 13005, France,
Tel + 33 0 4 13 73 24 01, Fax + 33 0 4 13 73 24 02, Email philippe.parola@univ-amu.fr; Jean-Christophe Lagier, Email jeanchristophe.lagier@ap-hm.fr
Objectives: We evaluated the 6-week mortality of SARS-CoV-2 hospitalized patients treated using a standardized protocol in 2020 in
Marseille, France.
Methods: A retrospective monocentric cohort study was conducted in the standard hospital wards at the Institut HospitaloUniversitaire Méditerranée Infection, between March and December 2020 in adults with SARS-CoV-2 PCR-proven infection.
Results: Of the 2111 hospitalized patients (median age, 67 [IQR 55–79] years; 1154 [54.7%] men), 271 were transferred to the
intensive care unit (12.8%) and 239 died (11.3%; the mean age of patients who died was 81.2 (±9.9)). Treatment with hydroxychloroquine plus azithromycin (HCQ-AZ), used in 1270 patients, was an independent protective factor against death (0.68 [0.52 –
0.88]). This effect was consistent for all subgroups of age, comorbidities, severity of the disease and comedications with zinc or
corticosteroids. Zinc was independently protective against death (0.39 [0.23 – 0.67]), in a subgroup analysis of patients treated with
HCQ-AZ without dexamethasone. The use of high-flow oxygen therapy in elderly patients who were not eligible for intensive care unit
transfer saved 19 patients (33.9%).
Conclusions: In our 2020 cohort, treating COVID-19 with HCQ-AZ was associated with lower mortality. These results need to be
analyzed in the context of academic discussions about observational studies versus randomized clinical trials. More data will deserve
to be analyzed in the SARS-Cov 2 variants, vaccination and post-vaccination era.
Keywords: SARS-CoV-2, COVID-19, hydroxychloroquine, azithromycin
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit